Is Teva-Amneal Inhaler Case A Double-Edged Sword For The Generics Industry?
Chad Landmon, Hatch-Waxman & Biologics Chair, discusses the Teva v. Amneal battle over inhaler patents in the FDA’s Orange Book, a case that is quickly becoming a landmark with the potential to impact both branded and generic drug companies.